Monday - July 24, 2017

Funds divided between Naomi House and Jacksplace and Newbury Athletic Club

Bayer Newbury 10k raises £13375 for charity

 Zoom image
Corporate fundraiser for Naomi House and Jacksplace, Jill McDonagh, left, and Becky Elsmere, Newbury AC, right, receive the cheque from Simon Greenstreet, Bayer.

Reading, 20 July, 2017: The tenth anniversary running of the Bayer Newbury 10K, on May 28, has raised just over £13,375 for charity.


A giant cheque was handed over to the two organisations nominated as the event’s charities this year: the hospices, Naomi House and Jacksplace, which provide support for children and young people with life limiting and life threatening conditions and their families, and Newbury Athletic Club, the race organisers.


Bayer’s head of Communications, Simon Greenstreet, who presented the cheque to representatives of the organisations in Newbury town centre, where the race was staged, said he was thrilled the 2017 event had reached such a successful conclusion.


“It takes a great deal of effort to put together such an important event, and there is a huge sense of pride that in the ten years that Bayer has sponsored the race, it has benefitted so many people. We have now donated £107,877 directly to deserving local causes, and would like to thank everyone who has helped make this possible.


“Many people have become involved in running as a result of being inspired by the Bayer Newbury 10k, and the event has helped to wave the flag for Newbury, becoming one of the highlights of the town’s community calendar. We should not forget also the thousands of runners who have raised money individually or as teams for charities of their own choice.”


Race director, Becky Elsmere, Newbury AC, said: “The race has continued to thrive and as joint recipients of its charitable donations over the years, we are very grateful to Bayer. We are delighted we’ve been able to put money directly into our sport which is enjoyed by so many children, young people and adults.


“In the meantime, we are already thinking about next year’s race, and are in discussions with potential sponsors, so we hope to be able to report on progress in the autumn.”


Fundraising manager for Naomi House, Clare Lay, added: “We are absolutely thrilled to have been supported by Bayer for another year, the money raised for us has such a huge impact on the hundreds of families that we care for. It costs just under £6,000 to run Naomi House for a day so this donation has truly facilitated our services – thank you.”



Notes to editors:

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to


Bayer media team: 0118 206 3000

Sara Bartlett: 07787 571020

Bayer’s offices in the UK and Ireland are located in Reading (head office), Cambridge and Dublin. For more information, go to

Follow us on Twitter at:

Follow us on Facebook

Follow us on YouTube at:


Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conformthem to future events or developments.